This article is available to members for free.

Goal: Recognize nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis (NFD/NSF) in patients with chronic kidney disease (CKD).

Objectives:

Identify the clinical manifestations of a patient presenting with NSF.
Discuss the FDA advisory concerning contrast enhanced MRI with gadodiamide in patients with CKD.
List the treatment options for NSP that are under investigation.

Note: The authors reported no actual or potential conflict of interest in relation to this continuing education article.

Loretta D. Ezell

Appearances